Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.72 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.72 |
| ▸ | GRIK1 | P39086 | 12/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060427 | 1.00 | AKR1C3 (0.72) | AKR1C3AKR1C2GRIK1MEN1KMT2A | |
| SCHEMBL5592996 | 0.90 | AKR1C3 (0.69) | AKR1C3AKR1C2GRIK1MEN1KMT2A | |
| SCHEMBL30832930 | 0.90 | AKR1C3 (0.69) | AKR1C3AKR1C2GRIK1MEN1KMT2A | |
| SCHEMBL9515604 | 0.90 | GRIK1 (0.69) | AKR1C3AKR1C2GRIK1MEN1KMT2A | |
| SCHEMBL7869107 | 0.89 | AKR1C3 (0.67) | AKR1C3AKR1C2GRIK1MEN1KMT2A | |
| SCHEMBL383535 | 0.88 | GRIK1 (0.74) | AKR1C3AKR1C2GRIK1MEN1KMT2A | |
| SCHEMBL3681838 | 0.87 | NPC1 (0.71) | AKR1C3AKR1C2GRIK1MEN1KMT2A | |
| SCHEMBL11646107 | 0.87 | MEN1 (0.66) | AKR1C3AKR1C2GRIK1MEN1KMT2A | |
| SCHEMBL4225722 | 0.87 | AKR1C3 (0.64) | AKR1C3AKR1C2GRIK1MEN1KMT2A | |
| SCHEMBL31500236 | 0.85 | AKR1C3 (0.70) | AKR1C3AKR1C2GRIK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4921875-A | Use of amino-substituted benzoic acids as remedies for diarrhea, and medicaments based on these compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-01 | — | — | US | claimed |
| EP-1341754-B1 | SUBSTITUTED ANTHRANILIC ACIDS | AVENTIS PHARMA GMBH (DE) | 2004-12-08 | — | — | EP | disclosed |
| EP-1341754-A1 | SUBSTITUTED ANTHRANILIC ACIDS | Aventis Pharma Deutschland GmbH (DE) | 2003-09-10 | — | — | EP | disclosed |
| US-6593352-B2 | 2-phenylalkylaminobenzoic acid containing substituted benzylsufamoyl group; useful for treating cardiovascular disorders, and for preserving or storing a transplant for surgery | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-07-15 | — | — | US | disclosed |
| US-20020123632-A1 | Substituted anthranilic acids, their use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-05 | — | — | US | disclosed |
| WO-2002046148-A1 | SUBSTITUTED ANTHRANILIC ACIDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-4921875-A | Use of amino-substituted benzoic acids as remedies for diarrhea, and medicaments based on these compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123632-A1 | Substituted anthranilic acids, their use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker | SLC10A1, SLC9A1, SLC9A2 | AKR1C3 682/4885AKR1C2 411/4885GRIK1 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.